World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston
Large pharma companies at World CDx 2026
Oct 5–8, 2026 Boston, MA ~900 attendees Website
18 large pharma companies are at World CDx 2026 — 52 presentations on the program. Most represented: Johnson & Johnson Innovative Medicine (7 on the program), EMD Serono (4 on the program), Merck (4 on the program). 11 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–9 of 18 organizations
| Organization | World CDx 2026 Attendance |
|---|---|
Johnson & Johnson Innovative Medicine New Brunswick, NJ | |
Pharmaceutical business of Johnson & Johnson, formerly Janssen, with medicines in oncology, immunology and neuroscience. | Talk Tue Oct 6 11:10am From Strategic Partnering to Orchestrated Partnering: Navigating the Next Era of Precision Medicine Drug–diagnostic commercialization & access Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Chair Wed Oct 7 11:19am Stream chair Talk Wed Oct 7 12:40pm MRD in IBD? Building a Precision Medicine Consortium for Deeper Endpoints in IBD Biomarker discovery & translation Talk Wed Oct 7 2:40pm If You Build It, Will They Come? Drug–diagnostic commercialization & access Panel Wed Oct 7 5:00pm Beyond the Contract: Inside a Pharma–CDx Partnership Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Thu Oct 8 8:10am Expanding Access to Precision Cancer Care with the Precision Cancer Consortium CGP Implementation Guide Drug–diagnostic commercialization & accessClinical & companion diagnostic development Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access Panel Thu Oct 8 2:00pm Fit-for-Purpose CDx Strategies: Matching Testing Approaches to Development & Patient Access Needs Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
EMD Serono Rockland, MA | |
US and Canadian healthcare business of Merck KGaA, Darmstadt, developing medicines in oncology, neurology, immunology and fertility. | Talk Tue Oct 6 11:30am A Dual Tissue & Liquid Biopsy Strategy: The TEPMETKO® Companion Diagnostic Journey Clinical & companion diagnostic developmentLiquid biopsy & MRD Chair Wed Oct 7 8:00am Chair’s Opening Remarks Talk Wed Oct 7 11:50am Definition of the Best Practices in Clinical Utility of Liquid Biopsy: Clinical Guideline, Technologies, Cost-Effectiveness, Reimbursement, a Unidirectional or Multidirectional Path Liquid biopsy & MRDDrug–diagnostic commercialization & access Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD Chair Wed Oct 7 4:05pm Chair’s Opening Afternoon Remarks Chair Wed Oct 7 5:50pm Closing Remarks & End of Conference Day Two |
Merck Rahway, NJ | |
US pharmaceutical company, known as MSD outside the US and Canada, with oncology medicines including pembrolizumab. | Panel Tue Oct 6 12:30pm Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Tue Oct 6 2:30pm Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment Clinical & companion diagnostic development Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD Panel Wed Oct 7 3:10pm Advancing Regulatory Frameworks & Standards for Compliant Digital Pathology Co-Development Digital pathology & spatial biomarkersClinical & companion diagnostic development Talk Thu Oct 8 12:20pm A Single-Cell Platform for Linking CRISPR-Edited Variants to Transcriptional Outcomes Biomarker discovery & translation Talk Thu Oct 8 12:20pm Drug Diagnostic Co-Development: Overlooked Challenges & Mitigations Clinical & companion diagnostic development |
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with medicines in oncology, hematology, immunology and cardiovascular disease. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Bolstering Scalable Commercial Drug-Diagnostic Strategies to Ensure Equitable Solutions for Global Precision Oncology Applications Drug–diagnostic commercialization & access Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 9:00am Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 12:10pm Building the Clinical & Commercial Ecosystem for AI-Enabled Precision Pathology Digital pathology & spatial biomarkersDrug–diagnostic commercialization & access Talk Thu Oct 8 9:50am When a Drug Program Expects Multiple Global Dx Partners: Considerations for Master CDx Agreements Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
AbbVie North Chicago, IL | |
Global pharmaceutical company with medicines in immunology, oncology, neuroscience and eye care, including antibody-drug conjugates for cancer. | Panel Tue Oct 6 2:00pm Single-Cell Becomes a Reality: The Next Generation of Therapy Selection Biomarkers Biomarker discovery & translation Talk Wed Oct 7 11:50am Strategic Considerations for Global Precision Medicine ADC Biomarker Launches Drug–diagnostic commercialization & accessClinical & companion diagnostic development Talk Wed Oct 7 2:10pm From Assay to Asset: How End‑to‑End Companion Diagnostic Partnerships Deliver Strategic Platform Selection, Clinical Development Alignment, & Reliable Execution Clinical & companion diagnostic development |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company with a large oncology portfolio, including targeted therapies and antibody-drug conjugates that rely on biomarker testing. | Talk Tue Oct 6 8:15am Enabling Access to Novel Computational Biomarkers: From Innovation to Impact Multimodal & AI-enabled precision medicineDrug–diagnostic commercialization & access Talk Wed Oct 7 11:50am Combining Foundation & Mathematical Models for Biomarker Discovery Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 3:10pm Realizing the Promise, Gaps & Platform Innovation for Precision Medicine at Scale from Global Technology Leaders Multimodal & AI-enabled precision medicine Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
Pfizer New York, NY | |
Global pharmaceutical company with medicines and vaccines across many areas, including oncology drugs such as antibody-drug conjugates. | Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 3:10pm Innovating Global Rx-Dx Trial Pathways Through Strategic & Compliant Co-Development Partnerships to Deliver Harmonized Precision Medicine Solutions Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
Gilead Sciences Foster City, CA | |
Biopharmaceutical company with marketed medicines in HIV, liver disease, oncology and inflammation, including antibody-drug conjugates and CAR T therapies. | Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 2:40pm Promise & Pitfalls of Tumor Target Quantification in Antibody-Drug Conjugate & Immune Cell Engager Drug Development Biomarker discovery & translationDigital pathology & spatial biomarkers |
Instantly find 20 buyers from large pharma companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World CDx 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by World CDx or its organizers. Submit a correction